Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Heron Therapeutics reports strong sales growth and successful product launches

Heron Therapeutics showcased strong sales growth and successful product launches in Q4 2022.
While facing challenges such as delayed EU launch and regulatory concerns, the company is focused on strategic growth opportunities.
Opportunities to increase product uptake and drive market penetration through targeted strategies were discussed.
Overall, Heron Therapeutics remains optimistic about future updates and growth prospects.

Heron Therapeutics reports strong Q1 earnings amidst product challenges

Heron Therapeutics' Q1 2023 performance reflects revenue growth and a strategic focus on key products despite operational challenges.
The company's strengths in product innovation and market potential position it well for future growth opportunities.
Addressing challenges in product uptake and operational efficiency will be crucial for Heron Therapeutics to sustain its positive momentum.
By leveraging opportunities in product expansion and strategic realignment, the company can enhance profitability and drive long-term success.

Heron Therapeutics reports revenue growth and strategic financing for future

Heron Therapeutics delivered solid revenue growth in Q2 2023, driven by strong sales performance in its oncology portfolio and strategic financing activities.
While facing operating losses, the company remains focused on cost-saving initiatives, product growth, and maximizing asset value to drive future profitability.
Opportunities lie in upcoming product expansions, market acceptance of new launches, and strategic partnerships to fuel Heron Therapeutics' growth trajectory.
With a resilient financial position and a clear strategic direction, Heron Therapeutics is poised for future success in the competitive pharmaceutical landscape.

Heron Therapeutics cuts costs, boosts margins, eyes revenue growth

Heron Therapeutics demonstrated strong financial discipline with reduced operational expenses and improving gross margins. Record-high unit sales of key products and a clear commercial strategy position the company for revenue growth. While facing financial challenges and aiming for profitability, Heron Therapeutics remains optimistic about the growth potential of its key products.

Heron Therapeutics exceeds revenue expectations, eyes profitability by Q4 2024

Heron Therapeutics delivered robust financial results in Q4 2023, driven by strong oncology franchise performance and strategic partnerships. With a focus on innovation, cost efficiency, and revenue expansion, the company aims to achieve positive EBITDA by Q4 2024 and capitalize on market opportunities for sustained growth.

Heron Therapeutics excels in Q1, eyes profitability by 2024

Heron Therapeutics made notable progress in Q1 2024, with achievements in product performance, revenue growth, and profitability targets.
While facing challenges in EBITDA variability and regulatory compliance, the company is well-positioned to capitalize on growth opportunities.
By leveraging strengths in sales strategies, R&D focus, and financial efficiency, Heron Therapeutics aims for sustained success in the market.
Overall, the company's strategic initiatives and strong financial outlook signal a positive trajectory for future growth and market expansion.

Heron Therapeutics (HRTX) reports robust Q2 performance and strategic growth plans

Heron Therapeutics (HRTX) delivered strong financial performance with revenue growth, improved margins, and effective expense control in Q2 2024.
Despite challenges like potential competition and regulatory uncertainties, HRTX's strategic strengths in product portfolio and partnerships position it for future success.
Opportunities for growth through product expansions, partnerships, and expense management strategies highlight a positive outlook for HRTX in the competitive market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products.

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference. The conference is being held in a virtual format, April 8-11, 2024.

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics

2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance ZYNRELEF® achieved quarterly record of $5.6 million in Q4 Net Product Sales Ended 2023 with cash and cash equivalents of $80.4 million Announced partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts on January 7, 2024 Received FDA approval for expanded indication of ZYNRELEF on January 23, 2024 SAN DIEGO , March 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2023 and highlighted recent corporate updates. "In the fourth quarter of 2023, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the Company for long-term success and profitability," said Craig Collard, Chief Executive Officer of Heron.

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Aldeyra Therapeutics

Esperion Therapeutics

Lyra Therapeutics

United Therapeutics

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy From a Rebounding Industry

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024, at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Heron Therapeutics has made progress in shoring up its balance sheet and cutting expenses, improving its financial position. Revenue growth remains a challenge. The expanded label for Zynrelef and the partnership with CrossLink could help accelerate growth in 2024.

Heron Therapeutics Is Out Of Survival Mode

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy

Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO , Jan. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Alkermes

MacroGenics

Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech companies. Investing in biotech and other pharmaceutical stocks can be risky because their price action can be so swift and unpredictable.

The 3 Most Undervalued Biotech Stocks to Buy in January

Heron Therapeutics, Inc. (HRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HRTX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy?

SAN DIEGO , Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network supporting ZYNRELEF® (bupivacaine and meloxicam) extended-release solution. The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout.

Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

HRTX's Zynrelef sales are back on track, with potential for significant growth pending approval of a supplemental New Drug Application. Aponvie sales have been underwhelming thus far and probably won't contribute much to HRTX's revenues in the near term. HRTX's financials show a net loss in Q3'23, but the completion of restructuring brings optimism for future profitability.

Heron Therapeutics Gets Back On Track

Heron Therapeutics develops solutions for pain and discomfort associated with chemotherapy and surgery, with four FDA-approved products. The company underwent a leadership change and implemented a plan to improve efficiency and profitability. Zynrelef, an opioid alternative, has the potential to become one of Heron Therapeutics' main value drivers.

Why Heron Therapeutics Is A Compelling Buy Into 2024

AC Immune

Clearsign Combustion

Perpetua Resources Corp

PowerFleet Inc

ReWalk Robotics

Synchronoss

Undeniably, the concept of growth penny stocks represent one of the hottest topics on Wall Street. And this interest goes well beyond the meme-stock phenomenon that characterized much of the market action during the post-pandemic period.

Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth

Globalstar

MoneyHero Ltd

The Metals Co

Penny stocks are highly speculative equities priced under $5 per share. They grab attention for their rapid rally potential even if the risks give most investors pause.

4 Penny Stocks To Watch Under $5; Are They A Buy Now?

Ondas Holdings

Taysha Gene Therapies

The world of penny stocks is interesting, offering the promise of significant returns for those willing to dive into this niche market. There aren't any guarantees that you'll immediately hit it big as a trader.

Which Penny Stocks Are Best? 3 That Insiders Like In November

Ardelyx

Altamira Therapeutics Ltd

LumiraDx Ltd

When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.

Penny Stocks To Buy? 4 Under $5 To Watch Right Now

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Jeff Cohen - Executive Director, Assistant General Counsel and Assistant Secretary Craig Collard - Chief Executive Officer Ryan Craig - Head of Marketing Ira Duarte - Executive Vice President, Chief Financial Officer Conference Call Participants Carl Byrnes - North Capital Market Nicholas Lorusso - TD Cowen Serge Belanger - Needham & Company Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Q3 2023 Earnings Conference Call.

Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million and full-year 2024 Net Product Sales to be in the range of $138 million to $158 million Full-year 2024 EBITDA (excluding stock compensation) expected to be in the range of ($22 million) to $3 million Cost reduction plan implemented decreasing operating expenses (excluding stock compensation and depreciation and amortization) by 26% in 2023 compared to 2022 and full-year 2024 operating expenses (excluding stock compensation and depreciation and amortization) are expected to be in the range of $108 million to $116 million SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2023 and highlighted recent corporate updates. Craig Collard, Chief Executive Officer, commented, "In just six months of initiating our corporate restructuring plan, I am pleased to announce its near completion.

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

SAN DIEGO , Nov. 7, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30 p.m. ET to report third quarter 2023 financial results and discuss recent business highlights.

News for Heron Therapeutics Stock (HRTX)